China Medical GatewayLoading your healthcare gateway…

Lymphoma in China

Overview

Lymphoma is a cancer of the lymphatic system, divided into Hodgkin and many non-Hodgkin subtypes. Accurate pathological subtyping drives everything: some lymphomas are cured with limited therapy, others need intensive immunochemotherapy or cellular therapy.

Chinese lymphoma centers run dedicated pathology units and high-volume immunochemotherapy programs, with CAR-T options for relapsed refractory B-cell disease.

Symptoms & Signs

Painless swollen lymph nodes in the neck, armpit or groin

Persistent fatigue and unexplained fevers or drenching night sweats

Unintentional weight loss exceeding 10% of body weight

Itching without rash, occasionally severe

Cough or breathlessness from chest disease; abdominal fullness from nodes or spleen

Some indolent lymphomas are monitored for years without symptoms requiring treatment

Diagnosis

Excisional lymph node biopsy — the essential diagnostic step, providing full architecture

Expert pathology review with immunohistochemistry and flow cytometry

PET-CT for staging and response assessment

Marrow biopsy evaluating involvement

Molecular and cytogenetic studies classifying subtype

Lumbar puncture for subtypes with central-nervous-system risk

Treatment Options

Immunochemotherapy (anti-CD20 antibody combined with chemotherapy) for aggressive B-cell lymphoma

Limited-field radiotherapy for early-stage Hodgkin and selected indolent lymphomas

Watch-and-wait with scheduled review for asymptomatic indolent disease

High-dose chemotherapy with autologous stem-cell rescue for relapsed aggressive disease

CAR-T cell therapy for relapsed refractory large B-cell lymphoma

Novel agents — BTK inhibitors, PI3K inhibitors, bispecific antibodies — for relapsed mantle-cell, follicular and other subtypes

Advanced Technologies & Novel Drug

Expert hematopathology with molecular subtyping

PET-CT response-adapted treatment strategies

CAR-T manufacturing and infusion programs

Bispecific antibody therapy available at major centers

Novel BTK inhibitors and targeted agents approved in China for multiple subtypes

Hospital & Specialist

Return to Home